The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Doximity, Inc. (DOCS) Investors

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). Doximity investors have until June 17, 2024 to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here to participate.

On August 8, 2023, Doximity released its first quarter fiscal year 2024 financial results and disclosed that it expected fiscal year 2024 revenue of between $452 million and $468 million, down from prior guidance of between $500 million and $506 million, representing year-over-year revenue growth of only between 7.9% and 11.7%, and adjusted EBITDA of between $193 million and $209 million, down from prior guidance of between $216 million and $222 million, representing year-over-year adjusted EBITDA growth of only between 4.9% and 13.6%. Additionally, the Company announced that it would be reducing its workforce by approximately 10%, which was expected to cost between $8 million to $10 million.

On this news, Doximity’s stock price fell $7.49, or 22.8%, to close at $25.30 per share on August 9, 2023, thereby injuring investors.

Then, on April 1, 2024, Jehoshaphat Research published a report alleging, among other things, that “Doximity’s underlying sales . . . are declining at a negative -3-6% rate, but that this decline has been masked through accelerated revenue recognition.”

On this news, Doximity’s stock price fell $1.11, or 4.1%, over two consecutive trading days to close at $25.80 per share on April 2, 2024, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants: (1) repeatedly touted the Company’s business prospects and the sustainability of the Company’s revenue growth and profitability, while downplaying the impact of competition and tightening macroeconomic conditions on the Company and Doximity’s reliance on “upselling” products and services (such as additional advertising) to existing customers to sustain the Company’s performance and future growth; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Doximity common stock during the Class Period, you may move the Court no later than June 17, 2024 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you purchased Doximity common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Doximity, Inc. (DOCS) Investors

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.